Three Cases of Sertoli-Leydig Cell Tumor.
- Author:
Jie Won PARK
1
;
Kyoung Ran YIM
;
Yong Min KIM
;
Ji Young KIM
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, Pochon CHA University, Seoul, Korea. callen1013@paran.com
- Publication Type:Case Report
- Keywords:
Sertoli-Leydig cell tumor
- MeSH:
Chemotherapy, Adjuvant;
Female;
Humans;
Hyperandrogenism;
Hysterectomy;
Lymph Node Excision;
Ovary;
Prognosis;
Recurrence;
Sertoli-Leydig Cell Tumor*;
Sex Cord-Gonadal Stromal Tumors;
Survival Rate;
Uterine Hemorrhage;
Virilism
- From:Korean Journal of Obstetrics and Gynecology
2006;49(3):682-689
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sertoli-Leydig cell tumors of the ovary are one of the sex cord-stromal tumors. They are very rare, account for less than 0.5% of all ovarian tumor. These tumors are almost unilateral, and occur predominantly at premenopausal state and rarely at postmenopausal and prepubertal. The most specific symptoms are virilization due to hyperandrogenism but it presents only in 40-50% of the patients, and vast majority of the patients complain for non-specific abdominal symptoms and menstrual disorder including vaginal bleeding. Prognosis and treatment modalities for Sertoli-Leydig cell tumors remain controversial as they are rare and only a few studies have been published. Treatment varies with patients age, tumor stage, and differentiation from unilateral salpingo-oophrectomy and total hysterectomy concomitant with pelvic lymph node dissection, and in occasion, adjuvant chemotherapy. Prognosis is generally favorable with 5-year survival rate of 70-90%. Recurrence is rare. We have experienced three cases of Sertoli-Leydig cell tumor, each of them showed different clinical presentation and histologic findings, so we present them with a brief review of literature.
